NCT07510724 (IKF-ReWoLuTe) is a clinical trial in Small Cell Lung Cancer (SCLC), sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest.

Who is sponsoring NCT07510724?

NCT07510724 is sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest.

What condition does NCT07510724 study?

NCT07510724 studies Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer (Diagnosis).

Is NCT07510724 still recruiting?

NCT07510724 is currently recruiting now. Last updated 3 April 2026.

Last reviewed 2026-04-03 · How we verify

NCT07510724: IKF-ReWoLuTe

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab

Recruiting now Last updated 3 April 2026

What this trial tests

trial in Small Cell Lung Cancer (SCLC) in 240 participants. Currently enrolling.

Timeline

23 December 2025

Primary endpoint
23 December 2032

23 January 2033

Quick facts

Lead sponsor	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	240
Start date	23 December 2025
Primary completion	23 December 2032
Estimated completion	23 January 2033
Sites	2 locations across Austria, Germany

Conditions studied

Small Cell Lung Cancer (SCLC) — all drugs for Small Cell Lung Cancer (SCLC) →
Non-Small Cell Lung Cancer (NSCLC) — all drugs for Non-Small Cell Lung Cancer (NSCLC) →
Lung Cancer (Diagnosis) — all drugs for Lung Cancer (Diagnosis) →

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest — full company profile →

Who can join

18 and older, any sex, with Small Cell Lung Cancer (SCLC) or Non-Small Cell Lung Cancer (NSCLC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The ReWoLuTe study (IKF091) is a prospective, multi-center, observational cohort study conducted in Germany and Austria to collect real-world data on the use of Tislelizumab-based therapies in patients with lung cancer. The study aims to evaluate the overall survival, treatment patterns, safety, and health-related quality of life of patients receiving Tislelizumab in everyday clinical practice.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Small Cell Lung Cancer (SCLC)

Currently open trials in the same condition.

NCT07480213 — Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) · Phase 1, PHASE2 · recruiting
NCT07434518 — A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC · recruiting
NCT07226999 — Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adul · Phase 2, PHASE3 · recruiting
NCT06745323 — A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC · Phase 2 · active not recruiting
NCT06485544 — Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial · Phase 2 · recruiting

Other Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest trials

Trials by the same sponsor.

NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07365930 — NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy · recruiting
NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
NCT06731803 — Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Re · Phase 1, PHASE2 · recruiting
NCT06123468 — Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07510724 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Last refreshed: 3 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07510724.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing